Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

• Status: Recruiting
• Trial end date: 2022-01-17
• Target enrollment: 0
• Participant gender: Female

Summary

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Brasileiro de Controle do Cancer
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Breast cancer hitologically confirmed

• 18 Years and older (Adult, Older Adult)

• Patients about to start use of Doxorubicine 60mg/m2 + Cyclophosfamide 600mg/m2

• No previous chemotherapy for breast cancer

Exclusion Criteria:

• Patients not capable of completing the questionnaire

• Patients with other condition that could cause nausea and emesis

• Use of opioids

• Use of antipsychotic medications

• Patients not capable of taking medications orally